A 46-year-old woman developed concurrent CMV and Pneumocystis carinii pneumonia (PCP) 140 days after autologous peripheral blood stem cell transplantation (APBSCT) for AML. She was seropositive for CMV before undergoing APBSCT and had required prednisone for immune thrombocytopenia and allergic dermatitis for 9 weeks prior to the onset of pneumonia. She had also been receiving PCP prophylaxis with pentamidine aerosol every month for 3 months before developing symptoms. The pneumonia was complicated by severe hypoxia, requiring ventilator support and pneumothorax requiring chest tube thoracostomy. She recovered following treatment with trimethoprim-sulfamethoxazole (TMP-SMX), prednisone, gancyclovir and intravenous immunoglobulin. Although the overall incidence of severe CMV disease is low after APBSCT, preventive measures such as surveillance culture and secondary prophylaxis with gancyclovir may be warranted in patients whose cellular immune response is further compromised by corticosteroid use or other factors.
Both Pneumocystis carinii and CMV can cause disease in individuals with severely impaired cell-mediated immune function. The risk of Pneumocystis carinii pneumonia (PCP) after BMT can be almost completely abrogated by prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMZ). 1, 2 The risk of CMV pneumonia after allogeneic BMT has been reduced by routine use of CMV-seronegative blood products in seronegative recipients, regular monitoring for CMV reactivation after transplant and prompt use of anti-CMV agent for suspected infection. ABMT is associated with an even lower risk of CMV pneumonia. [3] [4] [5] As a consequence, only a few cases of combined PCP and CMV disease following allogeneic or autologous BMT have been reported. 1, 5 To our knowledge, combined PCP and CMV disease has not been reported in patients following autologous peripheral blood stem cell transplantation (APBSCT). We report a patient treated with corticosteroids after APBSCT who developed concurrent PCP and CMV pneumonia.
Case report
A 46-year-old woman was admitted in June 1997 for abdominal pain in the right upper quadrant. On admission, her white blood cell count was 3.0 × 10 9 /l with 30% blasts, hemoglobin 81 g/l and platelet count 349 × 10 9 /l. Bone marrow examination demonstrated AML, M1 and cytogenetic analysis revealed a normal karyotype. She was seropositive for CMV and seronegative for HIV. She achieved remission after one cycle of induction chemotherapy with idarubicin 12 mg/m 2 once daily i.v. for 3 consecutive days and cytarabine 100 mg/m 2 by continuous i.v. infusion over 24 h for 7 consecutive days. Since she lacked a suitable bone marrow donor, she underwent consolidation with high-dose chemotherapy and APBSCT. The mobilization phase of treatment consisted of cytarabine 2 g/m 2 twice daily i.v. for 4 consecutive days, etoposide phosphate 60 mg/kg i.v. on day 5, followed by G-CSF 6 g/kg twice daily s.c. beginning on day 6. PBSC were harvested and cryopreserved on days 17 and 18. The conditioning regimen consisted of busulfan 4 mg/kg p.o. daily for 4 days (total dose 16 mg/kg) on days −7 to −4. She was to receive 60 mg/kg of etoposide phosphate on day −3, but developed an anaphylactic reaction. Therefore, etoposide phosphate was replaced with melphalan 100 mg/m 2 i.v. Cryopreserved PBSC were reinfused on day 0. She received prophylaxis with acyclovir, ciproflaxacin and fluconazole until neutrophil recovery. No prophylactic regimen against CMV was given. Her neutrophil count recovered to more than 0.5 × 10 9 /l by day 11, and her self-sustained platelet count recovered to more than 20 × 10 9 /l by day 13. TMP-SMX was then started for PCP prophylaxis. Her hematopoietic function continued to recover thereafter, until day 42 posttransplant when her platelet count dropped to 15 × 10 9 /l. Bone marrow examination revealed adequate megakaryocytes and no evidence of recurrent leukemia. Because of a lack of response to intravenous immunoglobulin (IVIG), and WinRho (Cangene, Winnipeg, Canada), prednisone 20 mg p.o. once daily was initiated for presumed immune thrombocytopenia. Despite these measures, her thrombocytopenia did not improve. With the concern of possible druginduced immune thrombocytopenia, TMP-SMX was discontinued and dapsone was started. However, after 2 weeks of treatment, dapsone was discontinued due to myelosuppression. Pentamidine aerosol 300 mg inhalation via Respirgard II (Marquest, Englewood, CO, USA) was started. On day 75 post-transplant, she developed a generalized skin rash and fever. Bacterial and viral cultures, including CMV, were negative. Skin biopsy revealed no evidence of GVHD. With the clinical diagnosis of allergic dermatitis, the dose of prednisone was increased to 60 mg p.o once daily on day 108, and her skin rash improved. Prednisone was gradually tapered down to 15 mg once daily. She developed fever without any other symptoms 140 days after transplant. Initial work-up was negative except for one blood culture from her central venous catheter which grew Coagulasenegative Staphylococcus. Since her therapy for AML had been completed, the catheter was removed, but her fever persisted, and she developed dyspnea 1 week later. A repeat chest radiograph showed bilateral diffuse interstitial infiltrates. An arterial blood gas analysis revealed PH 7.42, PaCO 2 32 mmHg, PaO 2 75 mmHg on 6 liters of nasal oxygen per min. She underwent bronchoscopy with transbronchial lung biopsy. Pneumocystis carinii was identified in the biopsy with Grocott methenamine silver staining. CMV shell vial culture (Intracel, Issaquah, WA, USA) of the bronchoalveolar lavage was positive. CMV shell vial culture of blood was negative. The histopathology of the lung biopsy revealed enlarged and cytologically atypical pneumocytes, but no inclusion bodies. CMV was not detected using immunohistochemical stains with a CMV monoclonal Ab (BioGenix, San Ramon, CA, USA) and a CMV DNA probe (Enzo Diagnostics, Farmingdale, NY, USA). She was started on TMP-SMX (TMP 20 mg/kg in divided doses daily i.v.), prednisone 40 mg p.o. twice daily, ganciclovir 5 mg/kg twice daily i.v., and IVIG 1 g/kg daily i.v. days 1-3, then weekly. On the second hospital day, she developed severe hypoxia and required ventilator support. On the third day, she developed a pneumothorax that was successfully treated with chest tube thoracostomy. She gradually improved and was extubated on day 6. After 3 weeks of antimicrobial therapy, she was discharged and continues to improve on oral therapy as an outpatient.
Discussion
With routine prophylaxis, PCP occurs in only about 1% of BMT recipients, the majority of which occurs in the absence of appropriate prophylaxis.
1,2
The risk of developing PCP is even lower in the setting of autologous transplantation. 2 Our patient had several risk factors for PCP. First, she was immunosuppressed during the recovery phase of APBSCT. 6 Second, she had been placed on prednisone for 9 weeks before her pneumonia occurred. Corticosteroid use has been an important risk factor for PCP in patients with hematologic disease. 7 In one study, 10 of 11 patients with the onset of PCP between 7-12 months post-BMT were on methylprednisolone. 8 Third, our patient had been receiving pentamidine aerosol before the onset of PCP. For PCP prophylaxis after BMT, TMP-SMX has been the drug of choice in most centers with pentamidine aerosol and dapsone being reserved for patients intolerant to TMP-SMX. 2 Nevertheless, both pentamidine aerosol and dapsone have been shown to be effective in phase II and retrospective studies. 9, 10 There are no randomized trials comparing these alternatives to TMP-SMX in the post-transplant setting. However, among HIV-positive patients, pentamidine aerosol and dapsone have been shown to be less efficacious than TMP-SMX. 11 Failure of pentamidine aerosol as PCP prophylaxis in APBSCT recipients has been reported. 2, 12 Our case also suggests that pentamidine inhalation may not be adequate for PCP prophylaxis in APBSCT, especially in patients treated with corticosteroids.
The rate of CMV infection in patients receiving autografts is around 40-50%, 3, 5 but CMV disease is less frequent compared with that in recipients of allografts. [3] [4] [5] The incidence of CMV pneumonia has varied from 0% to 8.6% in different centers, 13 with a significant mortality rate ranging from 56% to 100%. [3] [4] [5] [12] [13] [14] The diagnostic criteria for CMV pneumonia are inconsistent. In most studies, criteria for the diagnosis of CMV pneumonia have included pulmonary infiltrates, respiratory symptoms and CMV infection verified either by histology, virus isolation or immunologic staining from either BAL or lung biopsy.
3-5,12-14 Most researchers do not exclude patients with other etiologies of pneumonia, however a few do. 15 Pneumonia due to a combination of CMV and other micro-organisms is well documented. 1, 5, 7, 14 We can not completely rule out the possibility that our patient had PCP with viral shedding of CMV in respiratory secretions. However, our case fulfilled the conventional diagnostic criteria, and therefore anti-CMV therapy was indicated.
Concurrent disease by both CMV and PCP has been reported among BMT recipients, 1, 5 and other populations as well. 7 Tuan et al 1 reported four patients with PCP following BMT who had coexistent infection with CMV. Enright et al 5 reported two cases in which PCP contributed to the death of patients with CMV pneumonia in the post-BMT period. Whether these patients had undergone allogeneic or autologous transplantation was not specified. Our case demonstrates that concurrent PCP and CMV pneumonia may occur following APBSCT as well.
Immune reconstitution after hematopoietic stem cell transplantation has been found to vary by the source of stem cells in some, but not all studies. Roberts et al 6 found that APBSCT led to faster recovery of CD3 and CD4 cells, compared to ABMT and alloBMT. Talmadge et al 16 also found that there was more rapid immune reconstitution, including significantly improved CD4:CD8 cell ratio, NK cell number and function, PWM and PHA mitogenic response, and naive T lymphocytes response, following APBSCT, compared to that of ABMT. Whether the earlier immune recovery in APBSCT results in less PCP and CMV pneumonia would require large-scale studies.
In contrast to post-allograft CMV pneumonia, no risk factor has been consistently identified for post-autograft CMV pneumonia. In one study, CMV seropositivity prior to transplant, viruria and viremia were shown by a multivariate analysis to be significant risk factors for CMV pneu-monia following ABMT. 5 Grigg et al 12 recently reported two patients with CMV pneumonia, who had received fludarabine prior to transplant and corticosteroids after transplant. They speculated that the combination of fludarabine and corticosteroids may have increased the risk of CMV pneumonia. Our case and others demonstrate that corticosteroid therapy alone may further increase the level of posttransplant immunosuppression and lead to CMV disease. 17 Fatal CMV disease in patients receiving corticosteroids after APBSCT has been reported with increasing frequency. 12, 17 Therefore, a high index of suspicion for PCP and/or CMV disease is warranted in those patients treated with corticosteroids who develop unexplained fever, pulmonary infiltrates and hypoxia post-APBSCT. These patients may benefit from CMV preventive measures such as surveillance cultures and pre-emptive therapy.
